Abstract: TNF-alpha (Tumor Necrosis Factor-alpha) is a cytokine, a protein involved in the inflammation process in the body. It plays a crucial role in the immune system, primarily produced by activated macrophages the white blood cells. TNF-alpha is critical in the inflammatory response to infections and diseases, but it can also contribute to inflammatory and autoimmune diseases when produced in excess. Many antibodies are created to inhibit over-expressed TNF-alpha but with serious side effects. The present invention provides a mRNA vaccine to reduce the titer of TNF-alpha, leading to treating multiple life-threatening diseases including but not limited to rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, plaque psoriasis, inflammatory bowel disease, type 2 diabetes, tumor progression, angiogenesis, and metastasis, heart failure from myocardial cell death, and atherosclerosis from fibrosis.

Abstract: mRNA coding vaccines to treat neurodegenerative disorders (NDs), particularly Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD), Lewy Body Dementia (LBD), Multiple System Atrophy (MSA), Parkinson's Disease Dementia (PSD), and Progressive Supranuclear Palsy (PSP), to scavenge improperly folded or aggregated proteins 2MXU (PDB) (A?42), P10636 TAU_HUMAN (Tau Protein), P37840·SYUA_HUMAN (?-Synuclein), Q13148.TADBP_HUMAN (TDP-43), and P35637·FUS_HUMAN by generating specific antibodies based on the epitopes of these proteins. The epitopes can be linked to generate the open reading frames of mRNA vaccines.

Abstract: An mRNA composition for malaria prevention and treatment comprising a coding mRNA capable of expressing proteins and peptides of malaria pathogens, coming from linear epitopes and protein structure of antigens.

Abstract: Darbepoetin alpha treats anemia and it is traditionally manufactured using recombinant Chinese Hamster Ovary cells, a complex and expensive process; this invention reports an mRNA composition that encodes darbepoetin alpha in vivo as a therapeutic protein.

Abstract: The present invention provides a manufacturing process for liposomal preparations comprising water-insoluble or hydrophobic active principals. In accordance with one aspect of the inventive method, at least one active principal and lipid fraction are dissolved in an organic solvent. This solution is then subjected to reduced pressure (vacuum) in a container with or with out inert packing to remove the organic solvent, thereby forming a puffy cake comprising the active principal or principals and lipid fraction. This puffy cake is then mixed with an aqueous solution, under controlled conditions suitable to form a bulk liposomal preparation. Because the active principal is imbedded in the lipid bilayer, removal of the aqueous solution is optional.

Abstract: The present invention provides a composition comprising a physiologically acceptable carrier and two or more agents encapsulated in a liposome, wherein the combination of the two or more agents possess the following properties: (1) cytotoxicity to tumor cells, (2) nutritional properties, (3) use in application to nails, hair, skin or lips or (4) activity against parasites and insects. The invention also provides a method of making such a composition. The invention further provides a method of treating cancer when the combination of the two or more agents is cytotoxic to tumor cells.

Abstract: The present invention provides manufacturing processes for liposomal preparations. In accordance with the methods, a lipid fraction is dissolved in a water-miscible organic solvent. This solution comprising the lipid fraction can be added to and mixed with an aqueous solution under conditions to form a bulk liposomal preparation. Desirably, the preparation can include one or more active principals. The bulk liposomal preparation can be further processed as desired, for example, by size fractionation or reduction, removal of the water-miscible organic solvent, freeze-drying, or other treatment. The methods permit the production of liposomal formulations on a large or commercial scale.